{
  "meta": {
    "data_length": 1,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A475",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00496,
    "timestamp_received": "2026-09-25T01:16:40.377099+00:00Z",
    "timestamp_returned": "2026-09-25T01:16:40.382059+00:00Z",
    "trace_id": "b9407cba-9065-4996-99d9-422cf817f6e5"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:fda:imfinzi:2:1",
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-01-10:0",
          "type": "Contribution",
          "description": "Additional FDA approvals for initial version",
          "date": "2025-01-10",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:fda:2024-08-15:0",
          "type": "Contribution",
          "description": "Indication received traditional approval.",
          "date": "2024-08-15",
          "contributor": {
            "id": "agent:org:fda",
            "type": "Agent",
            "agentType": "organization",
            "name": "Food and Drug Administration",
            "description": "Regulatory agency that approves drugs for use in the United States."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda:imfinzi",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Imfinzi (durvalumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca UK Limited.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Imfinzi",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "durvalumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-05-01",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 761069,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-15",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:475",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:oncotree:NSCLC",
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "mappings": [],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:oncotree:NSCLC",
            "code": "NSCLC",
            "name": "Non-Small Cell Lung Cancer",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "txgrp:87",
          "membershipOperator": "AND",
          "therapies": [
            {
              "id": "tx:ncit:C376",
              "conceptType": "Therapy",
              "name": "Cisplatin",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:2555",
                    "code": "2555",
                    "name": "cisplatin",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2555"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:4301188",
                    "code": "4301188",
                    "name": "Cisplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4301188"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:sctid:387318005",
                    "code": "387318005",
                    "name": "Cisplatin",
                    "system": "SNOMED",
                    "systemVersion": "2026-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387318005&edition=MAIN/2026-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1397599",
                    "code": "1397599",
                    "name": "cisplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1397599"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Platinum-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C376",
                "code": "C376",
                "name": "Cisplatin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"
                ]
              }
            },
            {
              "id": "tx:ncit:C103194",
              "conceptType": "Therapy",
              "name": "Durvalumab",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:1919503",
                    "code": "1919503",
                    "name": "durvalumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1594034",
                    "code": "1594034",
                    "name": "durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1594034"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:sctid:735230005",
                    "code": "735230005",
                    "name": "Durvalumab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=735230005&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:42536415",
                    "code": "42536415",
                    "name": "Durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/42536415"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "PD-1/PD-L1 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C103194",
                "code": "C103194",
                "name": "Durvalumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"
                ]
              }
            },
            {
              "id": "tx:ncit:C66876",
              "conceptType": "Therapy",
              "name": "Gemcitabine",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:12574",
                    "code": "12574",
                    "name": "gemcitabine",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=12574"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1314924",
                    "code": "1314924",
                    "name": "gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1314924"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:sctid:386920008",
                    "code": "386920008",
                    "name": "Gemcitabine",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386920008&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:4305105",
                    "code": "4305105",
                    "name": "Gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4305105"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Antimetabolite"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C66876",
                "code": "C66876",
                "name": "Gemcitabine",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"
                ]
              }
            }
          ]
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:34",
                "present": true,
                "subject": {
                  "id": "bmkr:34",
                  "type": "CategoricalVariant",
                  "name": "Wild type ALK",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_004295.2, the protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5).",
                        "digest": "o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                          "type": "SequenceReference",
                          "name": "NP_004295.2",
                          "aliases": [
                            "ensembl:ENSP00000373700.3",
                            "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                            "refseq:NP_004295.2"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5), corresponding to the Refseq protein accession NP_004295.2.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 1620,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:427",
                        "conceptType": "Gene",
                        "name": "ALK",
                        "primaryCoding": {
                          "id": "coding:hgnc:427",
                          "code": "HGNC:427",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000171094",
                              "code": "ENSG00000171094",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000171094"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:238",
                              "code": "238",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/238"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_004304.5",
                              "code": "NM_004304.5",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Wild type"
                    }
                  ]
                }
              },
              {
                "id": "bmkr.criterion:35",
                "present": true,
                "subject": {
                  "id": "bmkr:35",
                  "type": "CategoricalVariant",
                  "name": "Wild type EGFR",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).",
                        "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "type": "SequenceReference",
                          "name": "NP_005219.2",
                          "aliases": [
                            "ensembl:ENSP00000275493.2",
                            "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                            "refseq:NP_005219.2"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 1210,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:3236",
                        "conceptType": "Gene",
                        "name": "EGFR",
                        "primaryCoding": {
                          "id": "coding:hgnc:3236",
                          "code": "HGNC:3236",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000146648",
                              "code": "ENSG00000146648",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000146648"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:1956",
                              "code": "1956",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/1956"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_005228.5",
                              "code": "NM_005228.5",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Wild type"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "25.01d",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:fda:imfinzi:2",
            "type": "Indication",
            "description": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors >= 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2025-01-10:0",
                "type": "Contribution",
                "description": "Additional FDA approvals for initial version",
                "date": "2025-01-10",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:fda:2024-08-15:0",
                "type": "Contribution",
                "description": "Indication received traditional approval.",
                "date": "2024-08-15",
                "contributor": {
                  "id": "agent:org:fda",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "Food and Drug Administration",
                  "description": "Regulatory agency that approves drugs for use in the United States."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:fda:imfinzi",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Imfinzi (durvalumab) [package insert]. FDA.",
                "title": null,
                "aliases": [],
                "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
                "urls": [
                  "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
                  "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:fda",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Food and Drug Administration",
                      "description": "Regulatory agency that approves drugs for use in the United States."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "AstraZeneca UK Limited.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Imfinzi",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "durvalumab",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2017-05-01",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": 761069,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2024-08-15",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}